Table 3.
Univariate analysis of baseline clinical features that associated with NGS detection ability.
| Clinical features | NGS + (N = 85) | NGS-(N = 14) | Statistics | P-value |
|---|---|---|---|---|
| Hypertension | 10 | 3 | 0.984 | 0.321 |
| CAD | 10 | 4 | 2.796 | 0.094 |
| Cerebrovascular disease | 15 | 3 | 0.116 | 0.734 |
| Previous cardiac surgery | 6 | 3 | 3.003 | 0.083 |
| Antibiotics used before admission | 37 | 6 | 0.002 | 0.962 |
| AR (cm2) | 6.0 (0–12.2) |
2.7 (0–9.6) |
469.000 | 0.201 |
| MR (cm2) | 8.0 (4.4–13.2) |
7.1 (2.7–10.3) |
511.500 | 0.402 |
| LVED (mm) | 57.0 (50.0–63.5) |
55.0 (51.7–60.2) |
561.500 | 0.736 |
| LVEF (%) | 64.0 (60.0–67.0) |
66.0 (43.0–69.5) |
574.500 | 0.837 |
| PCT (ng/mL) | 0.20 (0.06–0.87) |
0.10 (0.01–0.78) |
505.000 | 0.364 |
| CRP (mg/L) | 26.40 (8.39–63.06) |
13.15 (0.72–50.07) |
436.000 | 0.110 |
| ESR (mm/h) | 31.0 (11.0–54.7) |
31.0 (11.0–54.7) |
558.500 | 0.764 |
| WBC (109/L) | 7.97 (6.67–10.92) |
6.42 (5.07–8.54) |
377.000 | 0.029 |
| Neutrophil (109/L) | 5.68 (3.89–8.70) |
4.01 (3.23–5.97) |
396.500 | 0.046 |
| Lymphocyte (109/L) | 1.44 (1.03–1.90) |
1.26 (1.09–1.85) |
521.500 | 0.460 |
| Uric acid (umol/L) | 372.8 (282.3–451.0) |
398.7 (350.6–471.8) |
481.000 | 0.277 |
| BNP (pg/mL) | 2,433.0 (546.7–4655.5) |
2,758.5 (128.8–4709.7) |
554.500 | 0.684 |
| Troponin (pg/mL) | 24.7 (11.7–96.2) |
20.6 (8.8–59.9) |
539.500 | 0.577 |
| CK (U/L) | 40.0 (29.0–71.0) |
43.5 (32.7–153.5) |
480.000 | 0.247 |
| CKMB (U/L) | 10.0 (10.0–12.0) |
10.0 (5.09–13.6) |
588.500 | 0.946 |
CAD, coronary artery disease; AR, aortic regurgitation; MR, mitral regurgitation; LVED, center ventricular end-diastolic diameter; LVEF, center ventricular ejection fraction; PCT, procalcitonin; CRP, C-Reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell; BNP, B-type natriuretic peptide; CK, creatine kinase; CKMB, creatine kinase-MB.